Omission of Postoperative Radiation in HPV-Associated Oropharyngeal Cancer Using ctHPVDNA Surveillance (OPERATION)
Part of paid clinical trials in Charleston, South Carolina.
- Sponsor
- Medical University of South Carolina
- Study ID
- NCT07513389
- Phase
- PHASE2
- Status
- Recruiting
Conditions
- Human Papilloma Virus (HPV)
- Oropharyngeal Squamous Cell Carcinoma (OPSCC)
- Squamous Cell Carcinoma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Active Surveillance With ctHPVDNA (NavDx®) — OTHERActive surveillance without postoperative radiation using routine clinical follow-up and serial ctHPVDNA testing to detect recurrence.
Study Details
This single-arm Phase II trial evaluates whether omission of postoperative radiotherapy is feasible and oncologically safe in select patients with HPV-associated oropharyngeal squamous cell carcinoma (HPV-OPSCC). Eligible patients undergo transoral robotic surgery (TORS) and are observed without adjuvant radiation if they demonstrate low or intermediate pathological risk features and have negative circulating tumor HPV DNA (ctHPVDNA) two weeks post-operatively. Patients are followed with standard clinical surveillance combined with serial ctHPVDNA testing (NavDx®) to facilitate early detection of recurrence and prompt salvage therapy as needed.
Key Dates
- Start date
- Jul 1, 2026
- Status verified
- May 2026
- Primary completion
- Jul 1, 2029
- Completion
- Jul 1, 2030
Study Design
- Enrollment
- 36 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Active Surveillance With ctHPVDNA After SurgeryParticipants with negative postoperative ctHPVDNA are observed without adjuvant radiation and followed with routine clinical surveillance and serial ctHPVDNA testing.
Primary Outcome Measure
Local-Regional Control [ Time Frame: 2 years post-surgery ]
Central Contacts
- HCC Clinical Trials Office843-792-9321
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Medical University of South Carolina | Charleston | South Carolina | 29425 |
Find similar trials in Charleston, SC
Related Studies
- Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction DesignPHASE2 · Recruiting · Christopher Wilke · Pittsburgh, Pennsylvania
- T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung CancerPHASE2 · Recruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and NeckPHASE2 · Recruiting · Alain Algazi · San Francisco, California
- A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid TumorsPHASE1/PHASE2 · Recruiting · ImmVira Pharma Co. Ltd · Gilbert, Arizona